SecBot SecBot
8-K ·Filed Aug 12, 2026

STRO

SUTRO BIOPHARMA, INC.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-345733
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The STRO-004 early clinical data is the primary catalyst, validating the platform and de-risking the pipeline. Traders should monitor for the next STRO-004 update in 1H 2027 and the initiation of the STRO-006 Phase 1 trial in Q3 2026. The cash runway into Q2 2028 removes near-term financing risk.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

STRO drug pipeline →

STRO-004

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
Still in Phase 1 dose escalation; assuming successful Phase 1/2 and pivotal trials, potential approval would be several years away, likely 2029 or later.
Next catalyst
None dated

What to watchThe Phase 1 dose-escalation data from August 2026 showed early signals of activity (confirmed and unconfirmed partial responses) but also dose-limiting toxicities at the highest dose. The next update in H1 2027 will include expansion cohorts and more mature efficacy/safety data. Investors should watch for the dose selected for expansion, the durability of responses, and whether the safety profile supports a competitive advantage over the approved tissue-factor ADC Tivdak (tisotumab vedotin).

Price Chart

Loading chart...

Executive Summary

Sutro Biopharma reported Q2 2026 revenue of $9.8M (vs $63.7M YoY) and a net loss of $38.5M (EPS -$2.33 vs -$1.35 YoY), a significant decline from the prior year which included a large milestone payment. However, the stock catalyst is the early Phase 1 data for STRO-004, showing confirmed and unconfirmed partial responses in heavily pretreated pancreatic, head and neck, and NSCLC patients with a favorable tolerability profile and differentiated PK. The clinical validation of the platform is the primary driver, outweighing the weak financial quarter for a clinical-stage biotech.

Key Financial Metrics

EPS
−$2.33
est −$2.04 · -14.2%
Revenue
$9.8M
est $11.0M · -10.6% · -84.6% YoY
Rating
miss

Key Facts

  • Revenue was $9.8M for Q2 2026, down from $63.7M in Q2 2025, with the 2026 amount related principally to the Astellas collaboration.
  • Net loss was $38.5M (EPS -$2.33) vs $11.5M (EPS -$1.35) in Q2 2025.
  • Cash, cash equivalents and marketable securities were $164.3M as of June 30, 2026, expected to support operations into at least Q2 2028.
  • STRO-004 Phase 1 data shows confirmed and ongoing unconfirmed partial responses in pancreatic, head and neck, and NSCLC at dose levels 3-4 mg/kg.
  • Favorable tolerability profile with mostly low-grade AEs; discontinuation rate due to AEs was 6%.
  • STRO-004 has a half-life of nearly seven days, preserving 98% DAR8 configuration with low free payload.
  • STRO-006 on track to enter the clinic in Q3 2026; STRO-227 IND submission expected in 2026.
  • Second Astellas dual-payload iADC program expected to enter the clinic in 2H 2026.

Financial Impact

Revenue declined $53.9M YoY due to the absence of a large milestone payment; net loss widened by $27.0M. Cash burn of ~$38.3M in Q2.

revenuenet losscash

Risk Factors

  • STRO-004 data is early (Phase 1 dose escalation, n=49) with limited follow-up; responses are not yet durable.
  • Revenue is highly dependent on collaboration milestones, which are unpredictable.
  • Significant stockholders' deficit of $103.3M and deferred royalty obligation of $239.1M.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-345733
Document: stro-20260812.htm0001193125-26-345733
Document: stro-ex99_2.htm0001193125-26-345733
Document: 0001193125-26-345733-index-headers.html0001193125-26-345733
Document: 0001193125-26-345733-index.html0001193125-26-345733
Document: 0001193125-26-345733.txt0001193125-26-345733
8-K Data (Synthetic)0001193125-26-345733

Track record

8 reports on STRO

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +50.74% at T+20 after the Mar 23, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $9.82 to $9.32 Now $9.32 +5.09% ▲ +5.09% +3.18% vs SPY
  2. Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $10.61 to $10.17 Now $9.32 −12.16% ▼ −4.15% −3.78% vs SPY
  3. Aug 12, 202613w ago 8-K Bullish 7/10 Viewing No price data
  4. Aug 12, 202613w ago Press Release Mixed 6/10 Entry $21.30 to $21.31 Now $9.32 −56.24% ▲ +0.05% −0.65% vs SPY
  5. Apr 22, 202629w ago DEFA14A Neutral 3/10 Entry $34.83 to $33.33 Now $9.32 −73.24% ▼ −4.31% −5.09% vs SPY
  6. Apr 19, 202630w ago Press Release Bullish 7/10 Entry $34.58 to $34.35 Now $9.32 −73.05% ▼ −0.67% −0.01% vs SPY
  7. Mar 23, 202634w ago S-3 Bearish 6/10 Entry $23.57 to $23.50 Now $9.32 +60.46% ▲ +0.30% +0.86% vs SPY
  8. Mar 23, 202634w ago Press Release Bullish 7/10 Entry $23.57 to $23.50 Now $9.32 −60.46% ▼ −0.30% −0.86% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026